

1 **Identification of A Novel CG307 Sub-clade in Third Generation Cephalosporin Resistant**  
2 ***Klebsiella pneumoniae* Causing Invasive Infections in the United States**

3 Selvalakshmi Selvaraj Anand<sup>1</sup>, Chin-Ting Wu<sup>1</sup>, Jordan Bremer<sup>2</sup>, Micah Bhatti<sup>3</sup>, Todd J  
4 Treangen<sup>4</sup>, Awdhesh Kalia<sup>1</sup>, Samuel A Shelburne<sup>2,5#</sup>, William C Shropshire<sup>2</sup>

5 <sup>1</sup>Graduate Program in Diagnostic Genetics and Genomics, MD Anderson Cancer Center School  
6 of Health Professions, Houston, TX, USA

7 <sup>2</sup>Department of Infectious Diseases, Infection Control, and Employee Health, The University of  
8 Texas MD Anderson Cancer Center, Houston, TX, USA

9 <sup>3</sup>Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center,  
10 Houston, TX, USA

11 <sup>4</sup>Department of Computer Science, Rice University, Houston, TX, USA

12 <sup>5</sup>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center,  
13 Houston, TX, USA

14 #Address for correspondence: Samuel A Shelburne, MD, PhD, 1901 East Rd., South Campus  
15 Research Building, 4SCR5.1042, Houston, TX 77054; phone: (713) 792-7629, e-mail:  
16 [sshelburne@mdanderson.org](mailto:sshelburne@mdanderson.org)

17 **Keywords.** *3<sup>rd</sup> generation cephalosporin resistant Klebsiella pneumoniae, clonal group 307,*  
18 *multi-drug resistant K. pneumoniae surveillance, nosocomial transmission, accessory genome*

19 **ABSTRACT**

20 Despite the notable clinical impact, recent molecular epidemiology regarding third-generation  
21 cephalosporin-resistant *Klebsiella pneumoniae* (3GC-RKp) in the United States remains limited.  
22 We performed whole genome sequencing of 3GC-RKp bacteremia isolates collected from  
23 March 2016 to May 2022 at a tertiary care cancer center in Houston, TX using Illumina and  
24 Oxford Nanopore Technologies platforms. A comprehensive comparative genomic analysis was  
25 performed to dissect population structure, transmission dynamics, and pan-genomic signatures  
26 of our 3GC-RKp population. Of the 194 3GC-RKp bacteremias that occurred during our study  
27 timeframe, we were able to analyze 153 (79%) bacteremia isolates, 126 initial and 27 recurrent  
28 isolates respectively. While isolates belonging to the widely prevalent clonal group (CG) 258  
29 were rarely observed, the predominant clonal group, CG307, accounted for 37 (29%) index  
30 isolates and displayed a significant correlation (Pearson correlation test  $P$ -value = 0.03) with the  
31 annual frequency of 3GC-RKp bacteremia. Within our CG307 cohort, 89% (33/37) of our  
32 isolates belong to the global rather than previously described Texas-specific clade. Strikingly,  
33 we identified a new CG307 sub-clade (*i.e.*, cluster 1 isolates) comprised of 18 isolates  
34 characterized by the chromosomally-encoded *bla*<sub>SHV-205</sub> and unique accessory genome content.  
35 This CG307 sub-clade was detected in various United States regions, with genome sequences  
36 from 24 additional strains becoming recently available in the NCBI SRA database. Collectively,  
37 this study underscores the emergence and dissemination of a distinct CG307 sub-clade that is a  
38 prevalent cause of 3GC-RKp bacteremia among cancer patients seen in Houston, TX and has  
39 recently been isolated throughout the United States.

40 **DATA SUMMARY**

41 WGS data sequenced during this study period was submitted to NCBI and can be accessed  
42 within BioProject PRJNA648389. WGS data from previous study of carbapenem non-

43 susceptible *Enterobacterales* can be accessed from BioProject PRJNA836696. Assembly  
44 information and BioAccession numbers are provided in Table S1.

#### 45 **IMPACT STATEMENT**

46 Infections due to 3<sup>rd</sup> generation cephalosporin resistant *Klebsiella pneumoniae* (3GC-RKp) are  
47 considered among the most urgent public health threats. However, molecular epidemiology  
48 studies on 3GC-RKp in the United States are limited. Our analysis indicates a preponderance of  
49 genetically diverse 3GC-RKp isolates harboring the key antimicrobial resistance determinant  
50 *bla*<sub>CTX-M-15</sub> at our institution. Importantly, however, we detected evidence of long duration  
51 transmission of highly genetically related CG307 and CG29 specific clusters at our institution.  
52 Interestingly, we rarely detected the pandemic CG258 lineage in our cohort and did not detect  
53 more than two genetically related CG258 isolates from this lineage. We found that 90% of our  
54 isolates from the most prevalent clonal group, CG307, belonged to a novel, nested-population of  
55 a “global” CG307 clade in contrast to the more commonly detected “Texas-specific” clade that  
56 has circulated in our region. We searched the NCBI SRA database using genomic markers of  
57 the novel CG307 clade and found evidence of this clade causing recent invasive infections in  
58 other locations across the United States. Our study highlights the shifting population dynamics  
59 of *K. pneumoniae* causing invasive infections and the necessity to continue AMR surveillance in  
60 order to identify emerging high-risk populations.

## 61 INTRODUCTION

62 The necessity to address antimicrobial resistant (AMR) infections as a global public health  
63 threat has become increasingly apparent during the 21<sup>st</sup> century. A recent study estimated that  
64 4.95 million deaths were associated with AMR infections worldwide with *Klebsiella pneumoniae*  
65 infections being the third most common pathogen associated with mortality [1]. *K. pneumoniae*,  
66 a member of the *Enterobacterales* family, is an opportunistic pathogen that has the capacity to  
67 develop resistance to multiple classes of antibiotics. A recent meta-analysis estimated about  
68 33% of nosocomial *K. pneumoniae* infections are caused by MDR strains highlighting the impact  
69 of these pathogens in the healthcare setting [2].

70 MDR *K. pneumoniae* clonal populations can acquire  $\beta$ -lactamase encoding genes such as  
71 extended-spectrum  $\beta$ -lactamase (ESBL) or AmpC encoding genes via horizontal gene transfer  
72 (HGT), which results in third-generation cephalosporin resistance (3GC-R). These HGT plasmid  
73 vectors can also harbor carbapenemase encoding genes such as the *bla*<sub>KPC</sub>, which encodes the  
74 *Klebsiella pneumoniae* carbapenemase (KPC) that effectively hydrolyzes most classes of  $\beta$ -  
75 lactams [3-12]. One of the most concerning MDR *K. pneumoniae* clonal populations is the  
76 pandemic group of strains known as clonal group 258 (CG258), which include sequence types  
77 258 (ST258), ST512, and ST11, that are all closely related (*i.e.*, the CG258 average pairwise  
78 SNP distance is ~214) and strongly associated with worldwide *bla*<sub>KPC</sub> dissemination [6, 13-17].  
79 ST258 strains are the predominant MDR *K. pneumoniae* detected in the United States over the  
80 past two decades [5, 7, 16-19].

81 While ST258 prevalence has remained high in certain regions of the United States, there is  
82 growing evidence of an emergent CG307 lineage co-circulating with CG258 in the Houston, TX  
83 region [7, 9, 20, 21]. When performing comparative genomics between the two lineages, a  
84 discerning factor is the strong association of the ESBL encoding gene *bla*<sub>CTX-M-15</sub> that is present

85 in >90% of CG307 isolates whereas *bla*<sub>CTX-M-15</sub> is detected in <10% of CG258 isolates [9, 10,  
86 20]. Recent molecular epidemiological investigations of CG307 isolates have identified two  
87 predominant CG307 clades with a strong phylogenetic signal that distinguishes isolates of  
88 Texas origin from those from the more globally disseminated clade [10, 20]. When comparing  
89 the two ST307 lineages, the Texas-specific clade has a stable chromosomal insertion of two  
90 *ISEcp1-bla*<sub>CTX-M-15</sub> transposition units whereas the more globally disseminated CG307 lineage  
91 harbors *bla*<sub>CTX-M-15</sub> primarily on large, multireplicon, F-type conjugative plasmids [8, 10, 20].  
92 Furthermore, recent AMR surveillance studies from Europe have highlighted how CG307 strains  
93 are the primary drivers of 3GC-RKp (3GC-RKp) infections within hospitals in part due to their  
94 strong association with *bla*<sub>CTX-M-15</sub> carriage and transmission [22-24].

95 Given the high prevalence of CG307 in Houston and surrounding areas [7, 9, 20, 21, 25, 26] as  
96 well as a lack of current US-based 3GC-RKp surveillance studies, we sought to use WGS to  
97 determine the molecular epidemiology of 3GC-RKp causing bacteremia in cancer patients at our  
98 institution within a five-year timeframe. We found that CG307 strains were the most common  
99 CG detected whereas the previously highly prevalent CG258 was rarely identified. Interestingly,  
100 90% of CG307 bacteremias were caused by strains of the global clade; in particular, we  
101 identified that a previously unidentified, global sub-clade with distinct genomic signatures  
102 caused approximately 50% of the CG307 bacteremias at our institution. Search of publicly  
103 available WGS data identified isolates of this sub-clade recently collected from geographically  
104 diverse sites throughout the United States. These data expand upon the rapidly changing  
105 epidemiology of 3GC-RKp, including the increasing importance of emerging, diverse CG307  
106 sub-clades.

## 107 **METHODS**

### 108 **Study design and sample collection**

109 The study included all *K. pneumoniae* bacteremias that occurred from March 1<sup>st</sup>, 2016, chosen  
110 coincident with the date of implementation of the Epic Electronic Health Record system at the  
111 University of Texas MD Anderson Cancer Center (MDACC) in Houston, TX, to May 30<sup>th</sup>, 2022.  
112 We defined an index *K. pneumoniae* bacteremia isolate as first occurrence of a positive blood  
113 culture and a recurrent *K. pneumoniae* bacteremia isolate as a positive blood culture that  
114 occurred at least 14 days from a previous *K. pneumoniae* bacteremia isolate. Antibiotic  
115 susceptibility testing of all *K. pneumoniae* bacteremia isolates was performed by the MDACC  
116 microbiology laboratory using the Accelerate PhenoTest™ BC (Accelerate Diagnostics),  
117 ETEST® (bioMérieux), and VITEK® 2 (bioMérieux) with susceptibility interpretations based on  
118 CLSI guidelines [27]. *K. pneumoniae* bacteremia isolates were considered as extended-  
119 spectrum cephalosporin resistant (3GC-R) if they had a ceftriaxone (CRO) minimum inhibitory  
120 concentration (MIC)  $\geq 4$   $\mu\text{g/mL}$  and/or a predicted ESBL phenotype. Out of the 194 3GC-R*Kp*  
121 causing bacteremia during the study period, there were 79% (161/194) 3GC-R*Kp* isolates  
122 available for sequencing. Further information on sampling is included in the results section.

### 123 **Short-read and long-read sequencing**

124 3GC-R*Kp* isolates were stocked in thioglycolate broth supplemented with 40% glycerol as part  
125 of an ongoing surveillance of bacteremia isolates. This surveillance study has received ethical  
126 approval through the University of Texas MD Anderson Cancer Center (MDACC) Institutional  
127 Review Board (Protocol ID: PA13-0334). MicroBank (MB) numbers are unique to patient  
128 infections and deidentified. Samples were plated onto Trypticase Soy Agar (TSA with Sheep  
129 Blood). These plates were subsequently incubated overnight at 37°C and 4% CO<sub>2</sub>. After 12-24  
130 hours, a single colony was inoculated in autoclaved Miller's LB Broth and incubated at 37°C for

131 2 hours with mild agitation (225 rpm). Two mL of the inoculated media were aliquoted into 15  
132 mL Eppendorf tubes and spun down to pellet cells. Genomic DNA (gDNA) was extracted  
133 according to the protocol specified on QIAGEN “Blood and Cell Culture DNA Kit.” (Cat No.  
134 69581).

135 ESC-R-*K. pneumoniae* isolates were sequenced by Illumina NovaSeq 6000 as previously  
136 described [21]. There were 126 3GC-RKp isolates with 150 bp paired-end reads that passed  
137 quality control as assessed using fastqc-v0.11.9 (<https://github.com/s-andrews/FastQC>). We  
138 performed long-read sequencing on nine isolates of interest that were part of transmission  
139 clusters to obtain their complete genomes using the Oxford Nanopore Technologies (ONT)  
140 MinION platform as described previously [21]. Briefly, genomic DNA extracted for the purpose of  
141 short-read sequencing was used as input for ONT long-read sequencing. Library preparation  
142 was accomplished using the Rapid Sequencing Kit 96 V10 (SQK-RBK110.96). The input gDNA  
143 was normalized to 50 ng to ensure even distributions of libraries across pooled samples. The  
144 prepared libraries were loaded onto the R9.4.1 flowcell (FLO-MIN106D) for sequencing with  
145 MinKNOW software to generate fast5 files. Guppy-v6.4.6 basecaller was used to perform  
146 basecalling from the fast5 files to obtain fastq files using super high accuracy model (SUP).

#### 147 **Short and long-read sequencing data analysis**

148 Quality assessed, paired-end 150 bp reads were assembled via SPAdes-v3.15.5 [28] with  
149 default parameters and the inclusion of the isolate option. The quality assessment, assignment  
150 of sequence types, clonal groups, and capsule type of isolates was assessed using Kleborate-  
151 v2.2.0 with Kaptive-v2.0.0 activated [29, 30]. One genome assembly had Kleborate QC  
152 warnings due to ambiguous bases, genome size > 7.5 Mbp or < 4.5 Mbp, or N50 < 10 Kbp and  
153 was removed from analysis. The COpy Number Variant quantifiCation Tool (convict-v1.0) was  
154 used to identify antimicrobial resistance (AMR) from the ResFinder database (Accessed 2021-

155 11-09) and estimate gene copy numbers as described previously (Shropshire, W convict  
156 GitHub: <https://github.com/wshropshire/convict>) [21]. CONVICT as part of its pipeline employs  
157 the KmerResistance-2.0 bioinformatic tool that uses short-read k-mer alignment (KMA) to  
158 identify homologous AMR genes from redundant databases [31, 32]. The NCBI AMRFinderPlus  
159 command-line tool (v3.11.14) was used to confirm AMR gene identification from CONVICT  
160 using the NCBI curated database (version 2023-04-17.1).

161 A short- and long-read assembly pipeline (Shropshire, W flye\_hybrid\_assembly\_pipeline  
162 GitHub: [https://github.com/wshropshire/flye\\_hybrid\\_assembly\\_pipeline](https://github.com/wshropshire/flye_hybrid_assembly_pipeline)) was used to close  
163 complete genomes of ONT sequenced data as described previously [21]. Incomplete  
164 assemblies were re-assembled using Unicycler-v0.5.0 and manually curated for errors using  
165 short- and long-read pileups and visualizing with the integrated genome browser (IGV-v2.14.1)  
166 [33]. The high-performance computing (HPC) cluster, Seadragon, that is hosted through  
167 MDACC was used to perform genomic analyses. Sequencing QC, 3GC-R gene determinants,  
168 and antimicrobial susceptibility testing for isolates sequenced for this project in addition to  
169 previous MDACC studies is available in Table S1.

### 170 **Core Gene and Genome Analyses of 3GC-R*Kp* Isolates**

171 Genomes from index isolates (n=126) were annotated using Prokka-v1.14.5 and the annotation  
172 files in generalized feature format (GFF3) were used for the subsequent pan-genome analysis  
173 [34]. The gff3 files from Prokka were used to make a core gene alignment through Roary-v3.13  
174 using MAFFT-v7.4 [35, 36]. The index 3GC-R*Kp* core gene length was 3720547 bases. The  
175 pairwise SNP distances from the core gene alignment were identified using snp-dists-v0.8.4  
176 (<https://github.com/tseemann/snp-dists>). IQ-TREE-v2.0.6 was used to create a maximum  
177 likelihood phylogeny using the core gene alignment to determine the population structure [37].  
178 Bootstrap analysis was performed using UFBoot approximation and SH-like approximate



179 likelihood test with 1000 replicates though IQ-TREE-v2.0.6 [37, 38]. The tree visualization was  
180 performed using the R package ggtree-v3.9.1.

181 PopPUNK-v2.6.0 was used with index 3GC-RK $\rho$  draft assemblies (n=126) to identify potential  
182 cluster networks based on the core and accessory genome [39]. Following assignment, a core  
183 SNP phylogeny for each PopPUNK group was performed with a complete genome reference  
184 isolate using snippy-v4.6.0 (<https://github.com/tseemann/snippy>). The recombination regions  
185 were masked using Gubbins-v2.3.4 [36] and the filtered alignment file was used as the input file  
186 to obtain a core SNP maximum likelihood phylogeny using IQ-TREE-v2.0.6 [37]. The filtered  
187 polymorphic sites were used to generate pairwise SNP matrices to determine genetic  
188 relatedness within each specific PopPUNK group.

189 For CG307 population structure analysis, we performed a convenience sampling of publicly  
190 available CG307 isolates and oversampled for CG307 isolates harboring *bla*<sub>SHV-205</sub> alleles.  
191 CG307 short-reads were downloaded from NCBI using the sratoolkit-v2.10.9 through the  
192 fasterq-dump function (<https://github.com/ncbi/sra-tools>). SRA accession numbers and  
193 metadata for CG307 isolates are available on Table S2. A core SNP phylogeny for the CG307  
194 isolates was performed using Kp616 (GenBank Accession Number: GCA\_003076555.1) as a  
195 reference isolate using snippy-v4.6.0 as described in the paragraphs above. The Kp616 isolate  
196 was selected as a reference as it was previously used by Wyres et al. for comparing CG307  
197 population structure in addition to the genome being closed, completely resolved, and collected  
198 in 2009 [10]. The recombination regions were masked using Gubbins-v2.3.4 and a core SNP  
199 maximum likelihood phylogeny using IQ-TREE-v2.0.6 was performed as previously mentioned  
200 [37]. The per branch statistics output from Gubbins was analyzed to look for regions of high  
201 recombination.

202 A Bayesian analysis of population structure was performed using the core genome alignment  
203 through rhierBAPS-v1.0.1 to identify CG307 specific clusters[40]. Bayesian dating of the nodes  
204 of the CG307 phylogenetic tree was performed using BactDating-v1.1.0  
205 (<https://xavierdidelot.github.io/BactDating/>). The recombination free core SNP phylogenetic tree  
206 output from Gubbins-v2.3.4 was used to perform root-to-tip regression analysis prior to  
207 molecular dating (Fig. S1). The output timed tree was further annotated and visualized using R  
208 package ggtree-v3.9.1.


### 209 **Accessory genome analysis**

210 We used a subset of the accessory genome excluding low (<5%) and high frequency (>95%)  
211 genes for agglomerative hierarchical clustering of the gene presence/absence matrix from  
212 Roary to analyze the accessory genomes of CG307. Comparison of plasmid vectors with  
213 BLAST ring image generator (BRIG) was performed using the Proksee webserver [41]. Phage  
214 content in the genomes were characterized using the PHASTER webserver (<https://phaster.ca/>).  
215 Replicon types were identified using the “PlasmidFinder” database (Accessed 2023-07-01) with  
216 ABRicate-v1.0.0 (<https://github.com/tseemann/abricate>). Data visualization was generated using  
217 R-v4.0.4 packages or Geneious Prime software (2023.2.1).

### 218 **Statistical analysis**

219 Time series data were assessed using the Mann-Kendall Trend test. Comparisons between  
220 rates of *K. pneumoniae* bacteremias by 6-month groups were performed using Student's *t*-test.  
221 Chi-squared tests were used to compare group proportions between *K. pneumoniae*  
222 bacteremias. All statistics was computed on R-v4.0.4 or Prism 9 with a type one error rate  
223 ( $\alpha=0.05$ ) used across all hypothesis testing.

Rate=5.14e+00,MRCA=1997.34,R2=0.40,p<1.00e-04




224

225 **Fig. S1.** Initial root-to-tip correlation analysis of 224 CG307 isolates. Initial test of Gubbins  
226 phylogeny with an estimate  $\mu=5.14$  substitutions/genome, an MRCA = 1997, and significant  
227 test of temporal signal. Model testing with a null temporal signal (*i.e.*, all sampling dates equal)  
228 phylogeny indicates temporal signal model (model=carc) was significant. We found a strong  
229 correlation between the sampling dates and the root-to-tip distances in addition to the significant  
230 temporal signal ( $P$ -value<0.05). We selected for 10000 Markov Chain Monte Carlo simulations  
231 using a 'carc' model to obtain the dated phylogeny.

232 **RESULTS**

233 **Identification of higher 3GC-RKp bacteremia prevalence in latter half of annual periods**

234 Out of 668 *K. pneumoniae* bacteremias that occurred from March 2016 to May 2022, 83%  
235 (554/668) were index infections (*i.e.*, the first occurrence of patient *K. pneumoniae* bacteremia  
236 episode). There were 114 (17%) index bacteremias with one or more recurrent infections (*i.e.*,  
237 bacteremia occurring  $\geq 14$  days following an index bacteremia episode). 3GC-RKp infections  
238 accounted for 29% (194/668) of the *K. pneumoniae* bacteremias, of which 72% (139/194) were  
239 index infections. The proportion of index bacteremias that had recurrent episodes were  
240 significantly higher for 3GC-RKp (39%, 55/139) compared to third generation cephalosporin  
241 susceptible *K. pneumoniae* (3GC-SKp) infections (14%, 59/415,  $\chi^2$  *P*-value < 0.001). When  
242 normalized by the number of admissions to account for fluctuations in patient volume, the rates  
243 of index 3GC-RKp bacteremias were not significantly different over the course of the study  
244 (Mann Kendall trend test *P*-value > 0.05) (Fig. 1A). Similar to our recent study of 3GC-R  
245 *Escherichia coli* bacteremia [42], 3GC-RKp bacteremia prevalence was significantly higher in  
246 the last six months of the year relative to the first six months (0.67 vs. 0.45 bacteremias per  
247 month per 1,000 patient admissions respectively; Student's *t*-test *P*-value < 0.001) (Fig. 1B, 1C).  
248 No statistically significant difference in 3GC-SKp bacteremias stratified by time of year was  
249 observed (1.6 vs. 1.3 bacteremias per month per 1,000 patient admissions in 2nd half of year  
250 vs. 1st half of year, respectively; Student's *t*-test *P*-value = 0.07, Fig. 1C). These data indicate  
251 that for the past several years the rates of 3GC-RKp bacteremia have not been significantly  
252 changing and that environmental factors may contribute to 3GC-RKp infections.




253

254 **Fig. 1.** Epidemiology of *K. pneumoniae* bacteremias. (A) Index *K. pneumoniae* bacteremias by year. The x-axis shows the year, and  
 255 the y-axis (left) shows the normalized number of bacteremias with blue bars representing the 3GC-S*Kp* and red bars representing  
 256 the 3GC-R*Kp* infections, respectively. The y-axis (right) shows the proportion of 3GC-R*Kp* isolates amongst total *K. pneumoniae*  
 257 bacteremias (red-line). (B) *K. pneumoniae* bacteremias stratified by quarters of the year. The x-axis represents quarters of the year,  
 258 and the y-axis represents the normalized number of *K. pneumoniae* bacteremias with 3GC-R*Kp* (red) and 3GC-S*Kp* (blue) labelled  
 259 respectively. (C) Comparison of 3GC-R*Kp* and 3GC-S*Kp* bacteremia in the first half and the second half of the year. The red dots on  
 260 the left represent the average number 3GC-R*Kp* bacteremia for each month (e.g., January, February, etc.), and the blue dots on the  
 261 right represent the average number of 3GC-S*Kp* bacteremias by month. Student's *t*-test *P*-values are labelled accordingly.

262 **CG307 strains caused more 3GC-RKp bacteremias during study timeframe compared to**  
263 **other 3GC-RKp genotypes**

264 Out of the 194 3GC-RKp causing bacteremia during the study period, there were 79% (161/194)  
265 3GC-RKp isolates available (Fig. 2A) that met our study's inclusion criteria with 27 3GC-RKp  
266 isolates included from a previous study [21]. One index 3GC-RKp isolate had an assembly with  
267 genome size >7.5 Mbp and was excluded from the study. Further, we identified seven index  
268 3GC-RKp isolates (4%) that belonged to *K. pneumoniae* species complex taxa that were not *K.*  
269 *pneumoniae sensu stricto* and were thus excluded from analysis [4]. For the remainder of the  
270 study, all references to *K. pneumoniae* refer to *K. pneumoniae sensu stricto* strains. Thus, we  
271 had a total of 153 isolates with WGS data available for analysis with 126 index and 27 recurrent  
272 3GC-RKp isolates respectively (Fig. 2A). Among the 126 index isolates, there were a total of 52  
273 unique STs detected highlighting the genomic diversity of our cohort. When grouping isolates by  
274 sharing at least five of seven loci from the Pasteur MLST scheme (*i.e.*, clonal group  
275 designations), a total of 19 unique CGs were identified (Fig. 2B). The most predominant clonal  
276 group identified from our index 3GC-RKp isolates was CG307 (29%; 37/126) with all 37 isolates  
277 sharing identical ST307 schema. Interestingly, we only detected 6 index 3GC-RKp isolates (5%)  
278 that belonged to the pandemic CG258 lineage with ST258 (n=2), ST11 (n=2), and ST395 (n=2)  
279 identified. Additional to CG258 and CG307 isolates, we only identified clonal groups with 5 or  
280 more index 3GC-RKp isolates for CG29 (9/126; 7%), CG2947 (9/126; 7%), CG15 (8/126; 6%),  
281 and CG392 (6/126; 5%) with the remaining 40% (51/126) index 3GC-RKp isolates belonging to  
282 rarely identified clonal groups (*i.e.*, <5 matching clonal group isolates detected). When stratified  
283 by full calendar years in our sampling frame (Fig. 2C), CG307 remained the most frequent CG  
284 detected per year except in 2021 when CG392 (n=4) was the most common CG detected (*N.B.*,  
285 2016 and 2022 were excluded due to incomplete annual sampling). We observed a statistically  
286 significant positive correlation (Pearson correlation coefficient  $r=0.91$ ;  $P$ -value=0.03; Fig. 2D)  
287 between annual frequency of CG307 isolates collected and total 3GC-RKp infections detected

288 per year indicating that CG307 isolates may be the primary clonal group contributing to 3GC-  
289 *RKp* bacteremia prevalence.



290

291 **Fig. 2.** Whole genome sequencing workflow, clonal group distributions, and trends of 3GC-RKp  
 292 isolates. (A) Workflow of WGS inclusion/exclusion criteria for *K. pneumoniae* bacteremia  
 293 isolates. \*27 isolates from a previous study (BioProject Accession #: PRJNA836696) are  
 294 included in our analyses. (B) Pie chart showing the clonal group distribution of index 3GC-RKp  
 295 isolates. (C) Clonal groups of index 3GC-RKp isolates stratified by year. Legend indicates clonal  
 296 groups by color with gray representing index 3GC-RKp isolates that were not sequenced. (D)  
 297 Positive correlation between sequenced CG307 isolates per year (x-axis) and the total number  
 298 of index 3GC-RKp isolates from 2017-2021 (y-axis). Pearson's correlation coefficient ( $r$ ) with  
 299 associated correlation test  $P$ -value reported in figure.




### 300 **High genomic diversity within index 3GC-RKp core gene population structure**

301 To gain further insights into 3GC-RKp population structure, we performed a maximum-likelihood  
302 phylogeny inferred by a core gene alignment of index 3GC-RKp isolates (n=126) and identified  
303 diverse, deep-branching lineages often observed in MDR *K. pneumoniae* [4]. Using a core gene  
304 threshold definition of gene presence in  $\geq 99\%$  of cohort, 16% (3873/24209) of the pangenome  
305 was 'core' gene content reflecting substantial pangenome diversity. The median pairwise  
306 nucleotide divergence was 0.58% (median pairwise SNP distance [MPSD] = 21402)  
307 comparable to previous estimates [3, 20]. Although most CGs evidenced significant genetic  
308 diversity, there were clear clusters of closely related CG307 (MPSD = 84) and CG29 (MPSD =  
309 15) isolates (Fig. 3). Both the CG307 (KL102) and CG29 (KL19) isolates had highly conserved  
310 capsule locus (KL) genes compared to the other CGs (Fig. 3). Similar to the KL locus, the O-  
311 locus was highly conserved in CG307s (O2v2), CG29 (O1v2), and CG15 (O1v1) when  
312 compared to the other CGs. When analyzing the primary determinants of hypervirulent *K.*  
313 *pneumoniae* (hvKP) [29, 43], the siderophore yersiniabactin locus (*ybt*) was present in 31% of  
314 our 3GC-RKp population, consistent with the findings of Lam et al. 2018 [43]. Less commonly  
315 detected hvKP determinants were the genotoxin colibactin (*clb*, n=4), siderophore aerobactin  
316 (*iuc*, n=4), siderophore salmochelin (*iro*, n=1), and hypermucoidity *rmpADC* operon (n=1). One  
317 particularly interesting isolate belonged to ST412 (*i.e.*, MB3190), which is a member of  
318 hypervirulent-associated CG23, that harbored the *rmpADC* operon in addition to *iro1* and *iuc1*,  
319 often carried on the FIB<sub>k</sub> virulence plasmid KpVP-1 [43].

320 When focusing on the genetic determinants associated with 3GC-RKp, 94% (119/126) harbored  
321 AMR genes encoding enzymes that are associated with a 3GC-RKp phenotype. The  
322 overwhelming majority of 3GC-RKp isolates (n=109) harbored the ESBL encoding gene, *bla*<sub>CTX-</sub>  
323 <sub>M</sub> with 95% (104/109) harboring the *bla*<sub>CTX-M-15</sub> variant. We detected *bla*<sub>SHV-2be</sub> variants in eight  
324 strains, only two of which were identified using the NCBI AMRFinderPlus database with our

325 genomic assemblies; the remainder required the use of a short-read, k-mer mapping to  
326 database approach with KmerResistance to identify homologous *bla*<sub>SHV-2b</sub> and *bla*<sub>SHV-2be</sub> variants  
327 in the same strains. Additionally, CONVICT identified five strains with amplification of *bla*<sub>SHV-2b</sub>  
328 variants (*i.e.*, gene copy number of  $\geq 2.0\times$ ), with similar amplifications of penicillinase encoding  
329 genes associated with a 'false ESBL phenotype' [44]. A carbapenemase encoding gene was  
330 observed in 11 strains (9%) (*bla*<sub>KPC-2</sub>, n=5; *bla*<sub>OXA-48</sub>, n=2; *bla*<sub>OXA-181</sub>, n=2; *bla*<sub>OXA-232</sub>, n=2) (Fig. 3).  
331 In total, a putative genetic mechanism for the 3GC-R phenotype was present in 125/126 index  
332 3GC-RKp isolates (99%).

333 Given the extensive use of fluoroquinolones (FQs) as prophylaxis for neutropenic patients at our  
334 institution in addition to associated FQ resistance (FQR) and ESBL producing Gram-negative  
335 organisms [45], we next analyzed fluoroquinolone susceptibility and FQR mechanisms.  
336 Ciprofloxacin non-susceptibility was observed in 73% (92/126) of index 3GC-RKp isolates.  
337 Quinolone resistance determining region (QRDR) mutations in *gyrA* and *parC* were observed in  
338 50% (64/126) and 41% (52/126) of the strains, respectively, whereas the most commonly  
339 observed FQR mechanism in our cohort was the plasmid mediated FQR gene *qnr*, primarily  
340 *qnrB1*, observed in 79% (101/126) of the strains. Single and double QRDR mutation for *gyrA*  
341 were almost exclusively observed in the major CGs such as CG307, CG258, CG392, and  
342 CG15, whereas rare CGs typically lacked *gyrA* QRDR mutations but did contain *qnr* genes (Fig.  
343 3). The double mutation pattern *gyrA*-83+87 was present in 14 strains including four CG307s  
344 (Fig. 3).



345

346 **Fig. 3.** Core gene maximum-likelihood inferred phylogenetic analysis of index 3GC-RKp strains.

347 Phylogenetic tree is midpoint rooted with circular internal nodes representing 95% UFBoot

348 confidence values. Branch tips are labelled by clonal group with each CG highlighted within tree

349 structure. Rings are labelled as follows: 1) Capsule type; 2) O-antigen; 3) GyrA polymorphisms;

350 4) Plasmid-mediated fluoroquinolone resistance genes; 5) 3GC-R resistance genes; and 6)

351 Carbapenemase encoding genes.


352 **3GC-RKp transmission and recurrence dynamics driven primarily by CG307 and CG29**  
353 **clades**

354 Given the known capacity of 3GC-RKp to be transmitted in healthcare settings [2, 46], we used  
355 PopPUNK to identify nested populations of 3GC-RKp and subsequently performed PopPUNK  
356 cluster specific, core genome alignment inferred phylogenies masked for recombination to  
357 potentially identify transmission networks. We were able to identify 56 PopPUNK groups of  
358 which 14 included two or more isolates (*i.e.*, 42 isolates were uniquely divergent from the full  
359 cohort, consistent with our clonal group population structure). From these 14 PopPUNK groups,  
360 we identified 28 3GC-RKp isolates from unique patients that differed by <25 pairwise SNPs (*i.e.*,  
361 a SNP threshold that has been previously used to define potential *K. pneumoniae* transmission  
362 [47]) with a minimum of one other unique patient 3GC-RKp (Table S3). Potential strain  
363 transmission cluster sizes varied from 2-8 isolates with a median pairwise SNP distance of 8  
364 and range of 0-24 SNPs. Putative transmission clusters with genetically related pairwise isolates  
365 involved four distinct STs, namely ST307 (five clusters, 16 total isolates), ST29 (one cluster,  
366 eight isolates), ST152 (one cluster, 2 isolates), and ST280 (one cluster, 2 isolates).  
367 Interestingly, 97% (27/28) of index isolates from putative transmission clusters caused infections  
368 in patients with hematologic malignancy compared to 66% (65/98) non-clustered strains ( $\chi^2$  *P*-  
369 value < 0.001). The two largest transmission clusters (ST307 [pp8-1], n = 7; ST29, n = 8 [pp65-  
370 1]) both occurred over prolonged periods of time, 28 months for ST307 pp8-1 cluster and nearly  
371 60 months for the ST29 pp65-1 cluster in patients with multiple admissions and extensive  
372 contact with the healthcare system (Fig. 4A).


373 During the study timeframe, 12% (21/126) of index bacteremia patients had a recurrent 3GC-  
374 RKp bacteremia occurring an average of 94 days following the initial 3GC-RKp bacteremia  
375 episode (Fig. 4B). The same ST as the index isolate caused 91% of the recurrent infections.  
376 Consistent with carbapenems being the primary treatment for 3GC-RKp, 38% (8/21) of isolates

377 causing recurrent infections developed carbapenem resistance (Fig. 4B). The majority of strains  
378 (n=7) developed carbapenem resistance in the absence of a carbapenemase gene (*i.e.*, were  
379 non-carbapenemase producing carbapenem resistant *K. pneumoniae* or non-CP-CR*Kp*),  
380 whereas a single ST29 strain acquired *bla*<sub>KPC-2</sub> (Fig. 4BB). Through a combination of ONT long-  
381 read sequencing in addition to CONVICT gene copy number estimates, we found that six out of  
382 the seven non-CP-CRE recurrent isolates had evidence of *bla*<sub>CTX-M-15</sub> gene amplification (Fig.  
383 4C). Additionally, mutations in *ompK35* (n=1) and *ompK36* (n=4) were observed in 5/7 (71%) of  
384 the non-CP-CR*Kp* isolates (Fig. 4C). These data indicate that recurrence of 3GC-R*Kp*  
385 bacteremia primarily occurs due to re-infection by the same strain which has often developed  
386 carbapenem resistance through non-carbapenemase mechanisms.


**A**



**B**



**C**



387

388

**Fig. 4.** 3GC-RKp transmission and recurrence dynamics. (A) Genetically related (*i.e.*, <25

389

pairwise SNPs) isolates collected over time from unique patients for CG29 (top; dark green;

390 transmission cluster pp8-1) and CG307 (bottom; light blue; transmission cluster pp65-1) clades.  
391 Circles represent start and end of healthcare interactions at our institution for each respective  
392 patient with horizontal black line representing the duration of healthcare services. Red  
393 rectangles indicate collection date for each respective unique isolate. Note that patient-sample  
394 pair for MB12872 and MB11629 had end dates that went past 2021/12/31. (B) Index 3GC-RKp  
395 isolates with paired recurrent (*i.e.*, *K. pneumoniae* bacteremia isolate collected >14 days from  
396 antecedent index isolate). Duration of days from index to recurrent isolate is shown on the x-  
397 axis. Colors denote sequence type and shape indicates phenotypes as shown in legend. 3GC-  
398 RKp = third-generation cephalosporin resistant *K. pneumoniae*; CP-CRKp = carbapenemase  
399 producing carbapenem-resistant *K. pneumoniae*; Non-CP-CRKp = non-carbapenemase  
400 producing carbapenem-resistant *K. pneumoniae* (C)  $bla_{CTX-M}$  copy numbers and  
401 *ompK35/ompK36* mutation status in paired 3GC-RKp (left) and recurrent Non-CP-CRKp (right)  
402 isolates. Y-axis shows log<sub>2</sub> transformed  $bla_{CTX-M-15}$  copy number estimates. Shapes and colors  
403 show *ompK35/ompK36* status as delineated in the legend.


#### 404 **Identification of a novel lineage of CG307 causing bacteremia at our institution**

405 Given the stable detection of CG307 within the Houston region [7, 9, 20], including previously at  
406 our own institution [21], we further analyzed CG307 isolates from our cohort (n=37) along with a  
407 worldwide distribution of geographically diverse CG307 isolates (n=187) publicly available on  
408 NCBI. A Bayesian dated, recombination masked, phylogeny of 224 CG307s inferred from a core  
409 genome SNP alignment is presented on Fig. 5. Initial root-to-tip analysis of our CG307 cohort  
410 indicated a strong temporal signal (Fig. S1). Consistent with previous data, the CG307 splits into  
411 two primary clades consistent with the previously described “Texas-specific” (n =74) and  
412 “global” clades (n = 150). Within these respective CG307 clades, there were two nested sub-  
413 populations within each clade with clusters 3 and 4 belonging to the Texas-specific lineage and  
414 clusters 1 and 2 as part of the Global lineage [10, 20]. The Texas-specific clade harbored  
415 double GyrA-83I-87N mutations and 2× copies of *bla*<sub>CTX-M-15</sub> that have previously been  
416 characterized (Fig. 5) [10]. Interestingly, only four CG307 isolates in our cohort clustered with  
417 the Texas-specific clade. In contrast, the majority (n=33) of our CG307 isolates belonged to the  
418 global clade with an approximate even split between nested populations (18 and 15 isolates in  
419 clusters 1 and 2 respectively).

420 Our Bayesian dating analysis of our phylogeny estimates CG307 emerged in 1995 (95%  
421 confidence interval [95%CI]: 1991 – 1997), consistent with a previous estimation of CG307  
422 emergence in 1994 [10]. The date of divergence between the Texas-specific and global CG307  
423 clades is estimated to have occurred in 1997 (95%CI: 1995 – 2000) shortly after CG307 had  
424 emerged, suggesting that CG307 may have originated from the Houston region as previously  
425 hypothesized [10]. When focusing on the global clade, cluster 1 strains were estimated to  
426 emerge from cluster 2 strains approximately 1999 (95%CI: 1998-2001) with cluster 1 isolates  
427 beginning to clonally expand near 2008 (95%CI: 2006-2011) (Fig. 5). A conserved genomic  
428 feature of cluster 1 CG307 strains was the stable vertical transmission of *bla*<sub>SHV-205</sub>, a single



429 amino acid variant of the chromosomal *bla*<sub>SHV-1</sub> gene (Fig. 5). Consistent with our estimation of  
430 cluster 1 strains emerging near 2008, all publicly available cluster 1 strains with metadata were  
431 isolated from 2016 onwards with 15/25 isolated since 2020. All but one strain (Paraguay 2020)  
432 came from the United States including such geographically diverse locales as Utah, Chicago,  
433 and New York and even included two strains isolated from dogs in Texas. Given that MDA has  
434 a broad geographic patient distribution, we analyzed the home location for each patient with a  
435 CG307 infection at our institution and found that regardless of the cluster of infecting isolates,  
436 most patients (31/37, 82%) were from Texas and the majority were from the Houston area  
437 (54%) (Fig. S1A). There were three patients from the United States who resided outside Texas  
438 all of whom were infected by strains of the global lineage as were the three patients from  
439 outside the United States (Fig. S1B). These data indicate that the global lineage of CG307  
440 caused the majority of CG307 infections even among our patients from Houston and the rest of  
441 Texas.



442

443 **Fig. 5.** Identification of unique CG307 sub-clade (*i.e.*, cluster 1) causing bacteremia at our

444 institution. Presented is a Bayesian dated, core SNP recombination masked, phylogeny of 224

445 CG307 strains using isolate Kp616 (BioSample Accession Number: SAMN08391417) as

446 reference. Tip colors indicate hierBAPS predicted taxa with clusters 1 and 2 belonging to the


447 previously identified global clade and clusters 3 and 4 being part of the Texas-specific clade.

448 Years indicate predicted dates of divergence from internal nodes of interest as estimated using

449 BactDating. Dates in parenthesis represent the 95% confidence interval. Metadata presented

450 on right columns include A) geographic location of isolate collection; B) presence of *gyrA*

451 mutations; and C) chromosomal *bla<sub>SHV</sub>* isoforms.



452

453 **Supplemental Fig. 2.** Geographic location of patient origin in which CG307 strains caused  
 454 bacteremia at our institution. (A) X-axis stratifies isolates by clusters identified using hierarchical  
 455 clustering. Colors of patient origin as shown in legend. (B) Geographical distribution from a  
 456 world, country, and state perspective. Isolates are colored by cluster as indicated in legend.


## 457 **Differing accessory genome content across each of the CG307 clades**

458 To gain further insight into the various CG307 clusters, we used our Illumina data in conjunction  
459 with ONT long-read sequencing to dissect accessory genome content and determine genomic  
460 context of 3GC-RK $\rho$  determinants. We subset all accessory genome content shared in greater  
461 than 5% but less than 95% of the CG307 population to look for gene presence/absence signals  
462 present across our four clades and observed a demarcation across the four clusters (Fig. 6A).  
463 We noted that there were global and Texas-specific clade differences in replicon type detection,  
464 which has been described in previous literature (Fig. 6B) [20]. The global clade had an  
465 enrichment of IncFII (84%) and IncFIB $\kappa$  (97%) whereas there were very few cluster 3 isolates  
466 with either replicon detected (IncFII [36%]; IncFIB $\kappa$  [20%]) (Fig. 6B). These multireplicon F-type  
467 plasmid differences correlates with *bla*<sub>CTX-M-15</sub> carriage differences between global and Texas-  
468 specific clades as previously described [10, 20]. As shown in Fig. S3A, both MB5730 (Cluster 4)  
469 and MB8806 (Cluster 3) from the Texas-specific clade harbored 2 copies of *bla*<sub>CTX-M-15</sub> inserted in  
470 the chromosome. Conversely, isolates MB7606 (Cluster 2) and MB8674 (Cluster 1) from the  
471 global clade harbored *bla*<sub>CTX-M-15</sub> in association with IS26 pseudo-compound transposons made of  
472 two or more IS26 units with directly flanking IS26 transposases on IncFIB $\kappa$  plasmids (Fig. S3B).

473 We focused on accessory genome differences between the global cluster 1 and cluster 2  
474 isolates to determine what was driving the potential emergence of cluster 1 in our region. We  
475 found that cluster 1 strains had a very high recombination to mutation (*r/m*) ratio of 16  
476 suggesting that recombination events were driving diversity in this clade. We found two  
477 recombination blocks in cluster 1 isolates that appeared to be regions that differed with cluster 2  
478 isolates (Fig. 6C). First, we found that, relative to cluster 2 strains, cluster 1 strains uniquely  
479 contain a 40 Kbp prophage-like region which contains numerous putative regulatory proteins as  
480 well as proteins of unknown function (Fig. 6C). Second, although both cluster 1 and cluster 2  
481 strains contain a type 6 secretion system (T6SS), cluster 1 strains lack a set of T6SS

482 effector/immunity proteins which are present in cluster 2 strains (Fig. 6D). Taken together, we  
483 conclude that the cluster 1 strains identified in our study are a distinct genetic branch of the  
484 global CG307 clade that have unique accessory gene content as well as are causing disease  
485 throughout the United States.





498

499 **Supplemental Fig. 3.** Analysis of CG307  $bla_{CTX-M-15}$  copy number and genomic context from  
 500 MDA 3GC-RKp isolates. (A) CG307 Texas-specific clade isolates (*i.e.*, cluster 3 and cluster 4)  
 501 that have two copies of  $bla_{CTX-M-15}$  present on the chromosome in association with *ISEcp1* as  
 502 previously described [49]. (B) CG307 global clade isolates (*i.e.*, cluster 1 and cluster 2) that  
 503 have  $bla_{CTX-M-15}$  present in one or more copies on F-type multireplicon plasmids.

504 **DISCUSSION**

505 *K. pneumoniae* is a major contributor to healthcare associated infections and can acquire  
506 resistance to a diverse array of antimicrobials thereby rendering treatment problematic [1, 50,  
507 51]. Given the limited molecular epidemiology of 3<sup>rd</sup> generation cephalosporin resistant *K.*  
508 *pneumoniae* (3GC-R*Kp*) in the United States, we characterized 126 index and 27 recurrent  
509 3GC-R*Kp* bacteremia isolates collected from 2016 to 2022 at our institution (Fig. 2A).  
510 Consistent with other worldwide MDR *K. pneumoniae* surveillance studies, we observed long-  
511 branching, genetically diverse 3GC-R*Kp* isolates [22, 23, 47, 52-55]; however, there were  
512 clusters of “global problem clones” including CG307, CG29, and CG15 isolates with evidence of  
513 limited transmission [4]. Moreover, through analysis of our patients and publicly available  
514 genomes, we have identified a previously uncharacterized *K. pneumoniae* CG307 sub-clade  
515 (*i.e.*, cluster 1) that caused 14% of our index 3GC-R*Kp* infections and has been isolated recently  
516 from multiple locations across the United States [26, 55].

517 A major impetus for our study were reports of a recent expansion of 3GC-R*Kp* in the United  
518 States [12, 56]; however, prospective data from active 3GC-R*Kp* surveillance is limited, and  
519 thus increases in incident 3GC-R*Kp* infections remain unclear [57]. During our study timeframe,  
520 we observed fairly stable absolute frequencies as well as admission adjusted prevalence of  
521 3GC-R*Kp* bacteremias (Fig 1). It has been suggested that increases in 3GC-R *Enterobacterales*  
522 infections in the United States have been largely driven by community-onset cases [50]. The  
523 genetic diversity of 3GC-R*Kp* isolates (Fig. 3) in conjunction with seasonal prevalence  
524 differences of 3GC-R*Kp* infections (Figs. 1B, 1C) suggest a possible community-wide  
525 dissemination in our region. These data are similar to those recently described for a hospital  
526 network in Australia in which comprehensive WGS of *K. pneumoniae* found that the majority of  
527 infections were caused by widespread circulation in the community rather than hospital  
528 transmission [47]. Consistent with our observation 3GC-R*Kp* infections tended to occur in the



529 warmer second half of the calendar year compared to the first half of the year, a multi-site  
530 surveillance study across several continents found that environmental factors associated with  
531 warmer months may increase incidence rates of *K. pneumoniae* infections [58]. Nevertheless,  
532 similar to a recent analysis on 3GC-R *E. coli* prevalence at our institution [42], we observed a  
533 statistically significant association only for 3GC-R*Kp* but not 3GC-S*Kp* infections. Thus, our  
534 results taken together with previous studies suggest that limiting 3GC-R*Kp* acquisition outside of  
535 the hospital is likely to be critical to mitigation efforts.

536 Although we had a long-branching, genetically diverse cohort of 3GC-R*Kp* isolates (Figs. 2, 3),  
537 we also observed numerous instances of potential hospital-based 3GC-R*Kp* transmission (Fig.  
538 4A). It is worth noting that given we only sampled 3GC-R*Kp* isolates collected from bacteremia  
539 infections, we are likely underestimating the true scope of transmission that could be occurring  
540 at our institution. Interestingly, transmission clusters almost exclusively were due to the  
541 “problem clones” CG307 and CG29 (Fig. 4A) and involved patients with hematologic  
542 malignancy, likely because of the propensity of such individuals to develop bacteremias  
543 following initial colonization [59]. Outbreaks of these two “global problem clones” have been  
544 described [60] although whether such transmission is happening due to direct human contact or  
545 being acquired from the hospital environment is not currently known. Interestingly, for both  
546 CG307 and CG29 strains, we observed highly genetically related bacteria causing infections  
547 over a several years’ time-frame (Fig. 4A), suggesting potential environmental sources as has  
548 been observed for *Pseudomonas* spp. [61] and vancomycin resistant *Enterococcus faecium*  
549 [62]. The lack of clear epidemiologic links between infected patients means that standard  
550 infection control approaches would be unlikely to detect such transmission events emphasizing  
551 the potential complementary role that WGS could play in infection control efforts if real-time data  
552 were available [63].

553 Recurrence is a major concern following treatment of 3GC-RKp infections [64, 65], and indeed  
554 we observed an approximate 20% recurrence rate when just considering bacteremias. The  
555 recurrent strain was nearly always the same ST and highly genetically related to the index  
556 isolate suggesting re-infection rather than acquisition of a new 3GC-RKp strain. Interestingly,  
557 the recurrent organism could either retain a 3GC-R, carbapenem-susceptible phenotype or  
558 transition to carbapenem resistance, usually without acquisition of a carbapenemase (Fig. 4B).  
559 Although data are limited, a few studies have found that intravenous carbapenem administration  
560 does not reliably eradicate ESBL positive *Enterobacterales* from the intestinal tract, presumably  
561 due to low carbapenem stool concentrations [66, 67]. Alternatively, it has been recently  
562 demonstrated that *Enterobacter* spp. can enter into a cell-wall deficient spheroplast capable of  
563 surviving carbapenem exposure and returning to normal growth once carbapenem pressure is  
564 removed, and thus carbapenem “tolerance” could have accounted for strain persistence [68].  
565 3GC-RKp isolates can also develop outright resistance to carbapenems in the absence of  
566 carbapenemase by limiting drug influx through porin mutations along with hyperproduction of  
567 *bla*<sub>CTX-M</sub> encoding enzymes, which we were able to demonstrate in multiple serial isolates using  
568 a long-read sequencing approach [21]. Remarkably, we collected many recurrent isolates  
569 months or years from the index isolate collection date (Fig. 4B) with minimal pairwise SNP  
570 differences (*i.e.*, < 10 SNPs), suggesting the long duration of colonization achievable by 3GC-  
571 RKp [69]. We envision that a strategy of targeted *K. pneumoniae* gastrointestinal tract  
572 decolonization, such as using CRISPR-based technologies, could be part of the future treatment  
573 of 3GC-RKp infections [70].

574 We were intrigued by the paucity of Texas-specific CG307 isolates in contrast to the Global  
575 CG307 clade collected in our cohort in addition to the relatively low number of CG258 isolates  
576 detected (Fig. 2). A study from a Houston-wide hospital system analyzing ESBL *K. pneumoniae*  
577 strains collected from 2011-2015 found similar numbers of CG307 and CG258 strains, an

578 unexpected result given the predominant prevalence of CG258 in most United States  
579 investigations [5, 9, 19]. A comparative genomics analysis of CG307 isolates found that the  
580 Texas-specific clade was genetically distinct from other CG307 strains circulating worldwide,  
581 with multiple chromosomal insertions of *bla*<sub>CTX-M-15</sub> and a fixed double GyrA mutation as a  
582 predominant genomic feature of the Texas-specific CG307 clade [10]. Another Houston based  
583 study found divergent accessory genomes between CG258 and CG307 with greater plasmid  
584 content in the latter, suggesting that CG307 isolates had potential greater capacity to adapt to  
585 selective pressures [20]. Nevertheless, this study found very few of the global CG307 clade  
586 circulating in their particular hospital system [20]. The reason for our finding that only a small  
587 fraction of CG307 isolates belong to the Texas lineage is not clear but might be due to temporal  
588 variation given our most recent sampling timeframe. Support for this hypothesis comes from the  
589 relatively recent isolation of CG307 strains from across multiple United States locales including  
590 Central Texas [26] and Mississippi that cluster together with the majority of our Global CG307  
591 isolates. These isolates have a distinct chromosomal SHV, lack the multiple copies of  
592 chromosomal *bla*<sub>CTX-M-15</sub> hypothesized to be important to the success of the Texas-specific  
593 lineage, and contain a unique accessory genome relative to other CG307 strains (Figs. 5, 6).  
594 Our findings mirror similar, recent clonal expansions of CG307 strains from the global lineage  
595 recently observed in Wales and Norway, suggesting that the United States may be in the early  
596 stages of dissemination of a CG307 Global sub-clade [22, 23].

597 We identified two major events distinguishing the Global CG307 cluster 1 and cluster 2 isolates.  
598 The cluster 1 strains contained a prophage that did not contain any clear virulence factors,  
599 although numerous open reading frames encoded proteins of unknown function and acquisition  
600 of exogenous DNA has been shown to influence the transcriptome of distant genes possibly  
601 through the presence of transcriptional regulators in the acquired DNA [71, 72]. Additionally,  
602 relative to cluster 1, cluster 2 strains had a distinct set of effector/immunity proteins from a type

603 6 secretion system (Fig. 6D). T6SS function as injection machinery that can directly puncture  
604 both eukaryotic and prokaryotic membranes and have been identified as contributing to *K.*  
605 *pneumoniae* pulmonary infection, gastrointestinal colonization, bacterial competition, and liver  
606 abscess formation [73-76]. Future work will be necessary to further functionally characterize  
607 potential differences in virulence and resistance factors contributing to each CG307 clades'  
608 respective success.

609 Although our study had many strengths, there are some limitations. First, our isolates were  
610 recovered from a single center and thus the generalizability of our findings are not known;  
611 however, our cancer center draws from a large geographic region, and Houston has been a  
612 notable center of 3GC-RK $\rho$  infections [9, 20]. Second, we only analyzed bloodstream infections,  
613 which limits our results' generalizability when it comes to other 3GC-RK $\rho$  infectious sources;  
614 nevertheless, given the invasive nature of bacteremia, this reduces likelihood of identifying false  
615 positive infections. Finally, the genetic diversity of 3GC-RK $\rho$  isolates meant that we could only  
616 analyze in-depth a few clonal groups even with a sufficient large sample size of over 150 3GC-  
617 RK $\rho$  samples sequenced.

618 In summary, we present a contemporary, comparative genomics-based analysis of 3GC-RK $\rho$   
619 causing invasive disease in immunocompromised patients. We found that a previously  
620 unrecognized CG307 sub-clade is causing significant disease both in Houston and in diverse  
621 locations across the United States suggesting ongoing spread of an MDR *K. pneumoniae* strain  
622 with unique accessory genome content. Our findings emphasize the continued need for 3GC-R  
623 *Enterobacterales* surveillance in addition to the efforts made to track carbapenem resistant  
624 strains.

## 625 **ACKNOWLEDGEMENTS**

626 We would like to thank the MDACC clinical microbiology lab for all their hard work in identifying,  
627 handling, and transferring these pathogenic strains of interest to us for our research projects.  
628 Core grant CA016672(ATGC) and NIH 1S10OD024977-01 grant provide funding for the  
629 Advanced Technology Genomics Core (ATGC) sequencing facility at MD Anderson Cancer  
630 Center. SSA was supported by Dell Family Fund for the School of Health Professional  
631 scholarship and CTW is supported by Peter and Cynthia Hu scholarship. WCS is supported  
632 through the National Institute of Allergy and Infectious Diseases (NIAID) T32 AI141349  
633 Training Program in Antimicrobial Resistance. Support for this study was also provided by the  
634 NIAID R21AI151536 and P01AI152999 for S.A.S. The authors acknowledge the support of the  
635 High-Performance Computing for research facility at the University of Texas MD Anderson  
636 Cancer Center for providing computational resources that have contributed to the research  
637 results reported in this paper.

## 638 **REFERENCES**

- 639 1. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a  
640 systematic analysis. *The Lancet* **2022**; 399:629-55.
- 641 2. Mohd Asri NA, Ahmad S, Mohamud R, et al. Global Prevalence of Nosocomial Multidrug-Resistant  
642 *Klebsiella pneumoniae*: A Systematic Review and Meta-Analysis. *Antibiotics* **2021**; 10:1508.
- 643 3. Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence,  
644 and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad*  
645 *Sci U S A* **2015**; 112:E3574-81.
- 646 4. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat Rev Microbiol*  
647 **2020**; 18:344-59.
- 648 5. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae*  
649 isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents*  
650 *Chemother* **2009**; 53:3365-70.
- 651 6. Bowers JR, Kitchel B, Driebe EM, et al. Genomic Analysis of the Emergence and Rapid Global  
652 Dissemination of the Clonal Group 258 *Klebsiella pneumoniae* Pandemic. *PLoS One* **2015**; 10:e0133727.
- 653 7. Castanheira M, Farrell SE, Wanger A, Rolston KV, Jones RN, Mendes RE. Rapid expansion of KPC-2-  
654 producing *Klebsiella pneumoniae* isolates in two Texas hospitals due to clonal spread of ST258 and  
655 ST307 lineages. *Microbial Drug Resistance* **2013**; 19:295-7.
- 656 8. Villa L, Feudi C, Fortini D, et al. Diversity, virulence, and antimicrobial resistance of the KPC-producing  
657 *Klebsiella pneumoniae* ST307 clone. *Microb Genom* **2017**; 3:e000110.

658 9. Long SW, Olsen, R. J., Eagar, T. N., Beres, S. B., Zhao, P., Davis, J. J., ... & Musser, J. M. Population  
659 genomic analysis of 1,777 extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* isolates,  
660 Houston, Texas: unexpected abundance of clonal group 307. *MBio* **2017**; 8:e00489-17.

661 10. Wyres KL, Hawkey J, Hetland MAK, et al. Emergence and rapid global dissemination of CTX-M-15-  
662 associated *Klebsiella pneumoniae* strain ST307. *J Antimicrob Chemother* **2018**; 74:577-81.

663 11. Queenan AM, Bush K. Carbapenemases: the Versatile  $\beta$ -Lactamases. *Clinical Microbiology Reviews*  
664 **2007**; 20:440-58.

665 12. Castanheira M, Kimbrough JH, DeVries S, Mendes RE, Sader HS. Trends of beta-Lactamase  
666 Occurrence Among *Escherichia coli* and *Klebsiella pneumoniae* in United States Hospitals During a 5-Year  
667 Period and Activity of Antimicrobial Agents Against Isolates Stratified by beta-Lactamase Type. *Open*  
668 *Forum Infect Dis* **2023**; 10:ofad038.

669 13. Rojas LJ, Weinstock GM, De La Cadena E, et al. An Analysis of the Epidemic of *Klebsiella pneumoniae*  
670 Carbapenemase-Producing *K. pneumoniae*: Convergence of Two Evolutionary Mechanisms Creates the  
671 "Perfect Storm". *J Infect Dis* **2017**; 217:82-92.

672 14. Wang M, Earley M, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-  
673 resistant *Klebsiella pneumoniae* complex among patients from different global regions (CRACKLE-2): a  
674 prospective, multicentre, cohort study. *The Lancet Infectious Diseases* **2021**; 22:401-12.

675 15. David S, Reuter S, Harris SR, et al. Epidemic of carbapenem-resistant *Klebsiella pneumoniae* in  
676 Europe is driven by nosocomial spread. *Nat Microbiol* **2019**; 4:1919-29.

677 16. Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance reveals  
678 remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. *Proc Natl Acad Sci U S A*  
679 **2017**; 114:1135-40.

680 17. Satlin MJ, Chen L, Patel G, et al. Multicenter Clinical and Molecular Epidemiological Analysis of  
681 Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United  
682 States. *Antimicrobial Agents and Chemotherapy* **2017**; 61:AAC.02349-16.

683 18. van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant  
684 Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. *The Lancet Infectious Diseases*  
685 **2020**; 20:731-41.

686 19. Deleo FR, Chen L, Porcella SF, et al. Molecular dissection of the evolution of carbapenem-resistant  
687 multilocus sequence type 258 *Klebsiella pneumoniae*. *Proceedings of the National Academy of Sciences*  
688 **2014**; 111:4988-93.

689 20. Shropshire WC, Dinh AQ, Earley M, et al. Accessory genomes drive independent spread of  
690 carbapenem-resistant *Klebsiella pneumoniae* clonal groups 258 and 307 in Houston, TX. *MBio* **2022**;  
691 13:e00497-22.

692 21. Shropshire W, Konovalova A, McDaniel P, et al. Systematic Analysis of Mobile Genetic Elements  
693 Mediating  $\beta$ -Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant  
694 Enterobacterales Bloodstream Infections. *Msystems* **2022**; 7:e00476-22.

695 22. Fostervold A, Hetland MAK, Bakksjo R, et al. A nationwide genomic study of clinical *Klebsiella*  
696 *pneumoniae* in Norway 2001-15: introduction and spread of ESBLs facilitated by clonal groups CG15 and  
697 CG307. *J Antimicrob Chemother* **2022**; 77:665-74.

698 23. David S, Mentasti M, Sands K, et al. Genomic surveillance of multidrug-resistant *Klebsiella* in Wales  
699 reveals persistent spread of *Klebsiella pneumoniae* ST307 and adaptive evolution of pOXA-48-like  
700 plasmids. *Microbial Genomics* **2023**; 9.

701 24. Heiden SE, Hübner N-O, Bohnert JA, et al. A *Klebsiella pneumoniae* ST307 outbreak clone from  
702 Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron  
703 acquisition. *Genome Medicine* **2020**; 12:1-15.

704 25. Black CA, So W, Dallas SS, et al. Predominance of Non-carbapenemase Producing Carbapenem-  
705 Resistant Enterobacterales in South Texas. *Frontiers in Microbiology* **2021**; 11:3629.

706 26. Parker JK, Gu R, Estrera GA, et al. Carbapenem-Resistant and ESBL-Producing Enterobacterales  
707 Emerging in Central Texas. *Infection and Drug Resistance* **2023**; Volume 16:1249-61.

708 27. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. ed. Wayne, PA: Clinical  
709 and Laboratory Standards Institute, **2023**.

710 28. Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes De Novo Assembler.  
711 *Current Protocols in Bioinformatics* **2020**; 70:e102.

712 29. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework  
713 and genotyping tool for *Klebsiella pneumoniae* and its related species complex. *Nature Communications*  
714 **2021**; 12:4188.

715 30. Wyres KL, Wick R. R., Gorrie, C., Jenney, A., Follador, R., Thomson, N. R., & Holt, K. E. . Identification  
716 of *Klebsiella* capsule synthesis loci from whole genome data. *Microbial genomics* **2016**; 2:e000102.

717 31. Clausen PTLC, Zankari E, Aarestrup FM, Lund O. Benchmarking of methods for identification of  
718 antimicrobial resistance genes in bacterial whole genome data. *Journal of Antimicrobial Chemotherapy*  
719 **2016**; 71:2484-8.

720 32. Clausen PTLC, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads against redundant  
721 databases with KMA. *BMC Bioinformatics* **2018**; 19:1-8.

722 33. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. *Nature*  
723 *biotechnology* **2011**; 29:24-6.

724 34. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **2014**; 30:2068-9.

725 35. Page AJ, Cummins CA, Hunt M, et al. Roary: rapid large-scale prokaryote pan genome analysis.  
726 *Bioinformatics* **2015**; 31:3691-3.

727 36. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in  
728 performance and usability. *Mol Biol Evol* **2013**; 30:772-80.

729 37. Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New Models and Efficient Methods for  
730 Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* **2020**; 37:1530-4.

731 38. Hoang DT, Chernomor O, Von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast  
732 Bootstrap Approximation. *Molecular Biology and Evolution* **2018**; 35:518-22.

733 39. Lees JA, Harris SR, Tonkin-Hill G, et al. Fast and flexible bacterial genomic epidemiology with  
734 PopPUNK. *Genome Research* **2019**; 29:304-16.

735 40. Tonkin-Hill G, Lees JA, Bentley SD, Frost SDW, Corander J. RhierBAPS: An R implementation of the  
736 population clustering algorithm hierBAPS. *Wellcome Open Res* **2018**; 3:93.

737 41. Grant JR, Enns E, Marinier E, et al. Proksee: in-depth characterization and visualization of bacterial  
738 genomes. *Nucleic Acids Research* **2023**; 51:W484-W92.

739 42. Shropshire WC, Strobe B, Anand SS, et al. Temporal dynamics of genetically heterogeneous  
740 extended-spectrum cephalosporin-resistant *Escherichia coli* bloodstream infections. *mSphere* **2023**;  
741 0:e00183-23.

742 43. Lam MMC, Wick RR, Wyres KL, et al. Genetic diversity, mobilisation and spread of the yersiniabactin-  
743 encoding mobile element ICEKp in *Klebsiella pneumoniae* populations. *Microb Genom* **2018**; 4.

744 44. Beceiro A, Maharjan S, Gaulton T, et al. False extended-spectrum beta-lactamase phenotype in  
745 clinical isolates of *Escherichia coli* associated with increased expression of OXA-1 or TEM-1 penicillinases  
746 and loss of porins. *J Antimicrob Chemother* **2011**; 66:2006-10.

747 45. Wiener ES, Heil EL, Hynicka LM, Johnson JK. Are Fluoroquinolones Appropriate for the Treatment of  
748 Extended-Spectrum  $\beta$ -Lactamase-Producing Gram-Negative Bacilli? *Journal of Pharmacy Technology*  
749 **2016**; 32:16-21.

750 46. Weber A, Neffe L, Diaz LAP, et al. Analysis of transmission-related third-generation cephalosporin-  
751 resistant Enterobacterales by electronic data mining and core genome multi-locus sequence typing. *J*  
752 *Hosp Infect* **2023**; 140:96-101.

753 47. Gorrie CL, Mirceta M, Wick RR, et al. Genomic dissection of *Klebsiella pneumoniae* infections in  
754 hospital patients reveals insights into an opportunistic pathogen. *Nat Commun* **2022**; 13:3017.  
755 48. Li W, Liu X, Tsui W, et al. Identification and Comparative Genomic Analysis of Type VI Secretion  
756 Systems and Effectors in *Klebsiella pneumoniae*. *Front Microbiol* **2022**; 13:853744.  
757 49. Shropshire WC, Konovalova A, McDanel P, et al. Systematic Analysis of Mobile Genetic Elements  
758 Mediating Beta-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant  
759 Enterobacterales Bloodstream Infections. *Msystems* **2022**; 7:e00476-22.  
760 50. Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S.  
761 Hospitalized Patients, 2012–2017. *New England Journal of Medicine* **2020**; 382:1309-19.  
762 51. Arcari G, Carattoli A. Global spread and evolutionary convergence of multidrug-resistant and  
763 hypervirulent *Klebsiella pneumoniae* high-risk clones. *Pathog Glob Health* **2023**; 117:328-41.  
764 52. Ljungquist O, Haldorsen B, Pontinen AK, et al. Nationwide, population-based observational study of  
765 the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in  
766 Norway, 2015 to 2021. *Euro Surveill* **2023**; 28:2200774.  
767 53. Garcia-Gonzalez N, Fuster B, Tormo N, Salvador C, Gimeno C, Gonzalez-Candelas F. Genomic analysis  
768 of the initial dissemination of carbapenem-resistant *Klebsiella pneumoniae* clones in a tertiary hospital.  
769 *Microb Genom* **2023**; 9:001032.  
770 54. Thorpe HA, Booton R, Kallonen T, et al. A large-scale genomic snapshot of *Klebsiella* spp. isolates in  
771 Northern Italy reveals limited transmission between clinical and non-clinical settings. *Nature*  
772 *Microbiology* **2022**; 7:2054-67.  
773 55. Kochan TJ, Nozick SH, Medernach RL, et al. Genomic surveillance for multidrug-resistant or  
774 hypervirulent *Klebsiella pneumoniae* among United States bloodstream isolates. *BMC Infect Dis* **2022**;  
775 22:603.  
776 56. McDanel J, Schweizer M, Crabb V, et al. Incidence of Extended-Spectrum beta-Lactamase (ESBL)-  
777 Producing *Escherichia coli* and *Klebsiella* Infections in the United States: A Systematic Literature Review.  
778 *Infect Control Hosp Epidemiol* **2017**; 38:1209-15.  
779 57. Duffy N, Karlsson M, Reses HE, et al. Epidemiology of extended-spectrum  $\beta$ -lactamase-producing  
780 Enterobacterales in five US sites participating in the Emerging Infections Program, 2017. *Infection*  
781 *Control & Hospital Epidemiology* **2022**:1-9.  
782 58. Anderson DJ, Richet H, Chen LF, et al. Seasonal variation in *Klebsiella pneumoniae* bloodstream  
783 infection on 4 continents. *J Infect Dis* **2008**; 197:752-6.  
784 59. de la Court JR, Woudt SHS, Schoffelen AF, et al. Third-generation cephalosporin resistant gram-  
785 negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective  
786 study. *Ann Clin Microbiol Antimicrob* **2022**; 21:54.  
787 60. Gorrie CL, Mirceta M, Wick RR, et al. Antimicrobial-Resistant *Klebsiella pneumoniae* Carriage and  
788 Infection in Specialized Geriatric Care Wards Linked to Acquisition in the Referring Hospital. *Clin Infect*  
789 *Dis* **2018**; 67:161-70.  
790 61. Diorio-Toth L, Wallace MA, Farnsworth CW, et al. Intensive care unit sinks are persistently colonized  
791 with multidrug resistant bacteria and mobilizable, resistance-conferring plasmids. *Msystems* **2023**;  
792 8:e00206-23.  
793 62. El Haddad L, Hanson BM, Arias CA, et al. Emergence and Transmission of Daptomycin and  
794 Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms. *Clin Infect Dis* **2021**; 73:2306-  
795 13.  
796 63. Sundermann AJ, Chen J, Kumar P, et al. Whole-Genome Sequencing Surveillance and Machine  
797 Learning of the Electronic Health Record for Enhanced Healthcare Outbreak Detection. *Clin Infect Dis*  
798 **2022**; 75:476-82.



799 64. Mert D, Iskender G, Kolgelier S, Ertek M. Evaluation of risk factors, causative pathogens, and  
800 treatment in recurrent percutaneous nephrostomy catheter-related urinary tract infections in cancer  
801 patients. *Medicine (Baltimore)* **2023**; 102:e33002.

802 65. Refay SM, Ahmed EH, Abd ELzaher AR, Morsy AM, Yasser MM, Mahmoud AM. Risk of Drug  
803 Resistance and Repeated Infection with *Klebsiella pneumoniae* and *Escherichia coli* in Intensive Care  
804 Unit Cancer Patients. *Combinatorial Chemistry & High Throughput Screening* **2022**; 25:324-34.

805 66. Djukovic A, González-Barberá EM, Sanz J, et al. High heterogeneity of multidrug-resistant  
806 Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous  $\beta$ -lactams.  
807 Antimicrobial agents and chemotherapy **2020**; 64:e01415-19.

808 67. Gundes S, Arisoy AE, Kolyali F, et al. An outbreak of SHV-5 producing *Klebsiella pneumoniae* in a  
809 neonatal intensive care unit; meropenem failed to avoid fecal colonization. *The new microbiologica*  
810 **2005**; 28:231-6.

811 68. Murtha AN, Kazi MI, Schargel RD, et al. High-level carbapenem tolerance requires antibiotic-induced  
812 outer membrane modifications. *PLOS Pathogens* **2022**; 18:e1010307.

813 69. Herrera S, Torralbo B, Herranz S, et al. Carriage of multidrug-resistant Gram-negative bacilli: duration  
814 and risk factors. *Eur J Clin Microbiol Infect Dis* **2023**; 42:631-8.

815 70. Campos-Madueno EI, Moradi M, Eddoubaji Y, et al. Intestinal colonization with multidrug-resistant  
816 Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. *Eur J*  
817 *Clin Microbiol Infect Dis* **2023**; 42:229-54.

818 71. Roshika R, Jain I, Medicielo J, Wachter J, Danger JL, Sumbly P. The RD2 Pathogenicity Island Modifies  
819 the Disease Potential of the Group A Streptococcus. *Infect Immun* **2021**; 89:e0072220.

820 72. Vega LA, Sanson MA, Cubria MB, et al. The integrative conjugative element ICESpyM92 contributes  
821 to pathogenicity of emergent antimicrobial-resistant emm92 group A Streptococcus. *Infection and*  
822 *Immunity* **2022**; 90:e00080-22.

823 73. Wong Fok Lung T, Charytonowicz D, Beaumont KG, et al. *Klebsiella pneumoniae* induces host  
824 metabolic stress that promotes tolerance to pulmonary infection. *Cell Metab* **2022**; 34:761-74 e9.

825 74. Merciecca T, Bornes S, Nakusi L, et al. Role of *Klebsiella pneumoniae* Type VI secretion system (T6SS)  
826 in long-term gastrointestinal colonization. *Sci Rep* **2022**; 12:16968.

827 75. Storey D, McNally A, Astrand M, et al. *Klebsiella pneumoniae* type VI secretion system-mediated  
828 microbial competition is PhoPQ controlled and reactive oxygen species dependent. *PLoS Pathog* **2020**;  
829 16:e1007969.

830 76. Wang H, Guo Y, Liu Z, Chang Z. The Type VI Secretion System Contributes to the Invasiveness of Liver  
831 Abscess Caused by *Klebsiella pneumoniae*. *J Infect Dis* **2023**; 228:1127-36.

832